Ewing's sarcoma (ES) is a poorly differentiated pediatric tumor of aggressive behavior characterized by propensity to metastasize to bone. Interactions between the tumor and bone cells orchestrate a vicious cycle in which tumor cells induce osteoclast differentiation and activation to cause osteolytic lesions, broken bones, pain, and hypercalcemia. The lack of controllable models that can recapitulate osteolysis in ES impedes the development of new therapies and limits our understanding of how tumor cells invade bone. In response to this need, tissue-engineered models are now being developed to enable quantitative, predictive studies of human tumors. In this study, we report a novel bioengineered model of ES that incorporates the osteolytic process. Our strategy is based on engineering human bone containing both osteoclasts and osteoblasts within three-dimensional mineralized bone matrix. We show that the bone matrix is resorbed by mature osteoclasts while the new bone matrix is formed by osteoblasts, leading to calcium release and bone remodeling. Introduction of ES cell aggregates into the bone niche induced decreases in bone density, connectivity, and matrix deposition. Additionally, therapeutic reagents, such as zoledronic acid, which have demonstrated efficacy in ES treatment, inhibited bone resorption mediated by osteoclasts in the tumor model.
Get full access to this article
View all access options for this article.
References
1.
KimlinL.C., CasagrandeG., and ViradorV.M.In vitro three-dimensional (3D) models in cancer research: an update. Mol Carcinog, 52, 167, 2013.
2.
ChitcholtanK., AsselinE., ParentS., SykesP.H., and EvansJ.J.Differences in growth properties of endometrial cancer in three dimensional (3D) culture and 2D cell monolayer. Exp Cell Res, 319, 75, 2013.
3.
van der WorpH.B., HowellsD.W., SenaE.S., PorrittM.J., RewellS., O'CollinsV., and MacleodM.R.Can animal models of disease reliably inform human studies? PLoS Med, 7, e1000245, 2010.
4.
LawlorE.R., and SorensenP.H.Twenty years on: what do we really know about Ewing Sarcoma and what is the path forward? Crit Rev Oncog, 20, 155, 2015.
5.
YamadaK.M., and CukiermanE.Modeling tissue morphogenesis and cancer in 3D. Cell, 130, 601, 2007.
6.
ClarkeB.Normal bone anatomy and physiology. Clin J Am Soc Nephrol, 3Suppl 3, S131, 2008.
7.
GuiseT.A., MohammadK.S., ClinesG., StebbinsE.G., WongD.H., HigginsL.S., VessellaR., CoreyE., PadaleckiS., SuvaL., and ChirgwinJ.M.Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res, 12, 6213s, 2006.
8.
ToomeyE.C., SchiffmanJ.D., and LessnickS.L.Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene, 29, 4504, 2010.
9.
LauY.S., AdamopoulosI.E., SabokbarA., GieleH., GibbonsC.L., and AthanasouN.A.Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma. Br J Cancer, 96, 1716, 2007.
10.
TaylorR., KnowlesH.J., and AthanasouN.A.Ewing sarcoma cells express RANKL and support osteoclastogenesis. J Pathol, 225, 195, 2011.
11.
David RoodmanG., and SilbermannR.Mechanisms of osteolytic and osteoblastic skeletal lesions. Bonekey Rep, 4, 753, 2015.
12.
RediniF., and HeymannD.Bone tumor environment as a potential therapeutic target in Ewing Sarcoma. Front Oncol, 5, 279, 2015.
13.
KingsleyL.A., FournierP.G., ChirgwinJ.M., and GuiseT.A.Molecular biology of bone metastasis. Mol Cancer Ther, 6, 2609, 2007.
14.
BurdettE., KasperF.K., MikosA.G., and LudwigJ.A.Engineering tumors: a tissue engineering perspective in cancer biology. Tissue Eng Part B Rev, 16, 351, 2010.
15.
SchuesslerT.K., ChanX.Y., ChenH.J., JiK., ParkK.M., Roshan-GhiasA., SethiP., ThakurA., TianX., VillasanteA., ZervantonakisI.K., MooreN.M., NagaharaL.A., and KuhnN.Z.Biomimetic tissue engineered systems for Advancing Cancer Research: NCI Strategic Workshop Report. Cancer Res, 74, 5359, 2014.
16.
PittengerM.F., MackayA.M., BeckS.C., JaiswalR.K., DouglasR., MoscaJ.D., MoormanM.A., SimonettiD.W., CraigS., and MarshakD.R.Multilineage potential of adult human mesenchymal stem cells. Science, 284, 143, 1999.
17.
GraysonW.L., BhumiratanaS., CannizzaroC., and Vunjak-NovakovicG.Bioreactor cultivation of functional bone grafts. Methods Mol Biol, 698, 231, 2011.
18.
GraysonW.L., FrohlichM., YeagerK., BhumiratanaS., ChanM.E., CannizzaroC., WanL.Q., LiuX.S., GuoX.E., and Vunjak-NovakovicG.Engineering anatomically shaped human bone grafts. Proc Natl Acad Sci U S A, 107, 3299, 2010.
19.
ChaoP.H., GraysonW., and Vunjak-NovakovicG.Engineering cartilage and bone using human mesenchymal stem cells. J Orthop Sci, 12, 398, 2007.
20.
de PeppoG.M., Marcos-CamposI., KahlerD.J., AlsalmanD., ShangL., Vunjak-NovakovicG., and MaroltD.Engineering bone tissue substitutes from human induced pluripotent stem cells. Proc Natl Acad Sci U S A, 2013.
21.
CrapoP.M., GilbertT.W., and BadylakS.F.An overview of tissue and whole organ decellularization processes. Biomaterials, 32, 3233, 2011.
22.
GraysonW.L., MartensT.P., EngG.M., RadisicM., and Vunjak-NovakovicG.Biomimetic approach to tissue engineering. Semin Cell Dev Biol, 20, 665, 2009.
23.
BhumiratanaS., BernhardJ.C., AlfiD.M., YeagerK., EtonR.E., BovaJ., ShahF., GimbleJ.M., LopezM.J., EisigS.B., and Vunjak-NovakovicG.Tissue-engineered autologous grafts for facial bone reconstruction. Sci Transl Med, 8, 343ra83, 2016.
24.
SorensenM.G., HenriksenK., SchallerS., HenriksenD.B., NielsenF.C., DziegielM.H., and KarsdalM.A.Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J Bone Miner Metab, 25, 36, 2007.
25.
JeonO.H., PanickerL.M., LuQ., ChaeJ.J., FeldmanR.A., and ElisseeffJ.H.Human iPSC-derived osteoblasts and osteoclasts together promote bone regeneration in 3D biomaterials. Sci Rep, 6, 26761, 2016.
26.
CapparielloA., MauriziA., VeeriahV., and TetiA.The Great Beauty of the osteoclast. Arch Biochem Biophys, 558, 70, 2014.
27.
BoyleW.J., SimonetW.S., and LaceyD.L.Osteoclast differentiation and activation. Nature, 423, 337, 2003.
28.
ManolagasS.C.Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev, 21, 115, 2000.
29.
RiggsB.L., and ParfittA.M.Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res, 20, 177, 2005.
30.
SchmidtC., KasparD., SarkarM.R., ClaesL.E., and IgnatiusA.A.A scanning electron microscopy study of human osteoblast morphology on five orthopedic metals. J Biomed Mater Res, 63, 252, 2002.
31.
SeibelM.J.Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev, 26, 97, 2005.
32.
MerryK., DoddsR., LittlewoodA., and GowenM.Expression of osteopontin mRNA by osteoclasts and osteoblasts in modelling adult human bone. J Cell Sci, 104 (Pt 4), 1013, 1993.
33.
CaoJ.J., and PickloM.J.N-acetylcysteine supplementation decreases osteoclast differentiation and increases bone mass in mice fed a high-fat diet. J Nutr, 144, 289, 2014.
34.
BrombergO., FrischB.J., WeberJ.M., PorterR.L., CivitelliR., and CalviL.M.Osteoblastic N-cadherin is not required for microenvironmental support and regulation of hematopoietic stem and progenitor cells. Blood, 120, 303, 2012.
35.
DrakeM.T., ClarkeB.L., and KhoslaS.Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc, 83, 1032, 2008.
36.
MansourA., AnginotA., ManciniS.J., SchiffC., CarleG.F., WakkachA., and Blin-WakkachC.Osteoclast activity modulates B-cell development in the bone marrow. Cell Res, 21, 1102, 2011.
37.
ArringtonS.A., SchoonmakerJ.E., DamronT.A., MannK.A., and AllenM.J.Temporal changes in bone mass and mechanical properties in a murine model of tumor osteolysis. Bone, 38, 359, 2006.
38.
BiX., SterlingJ.A., MerkelA.R., PerrienD.S., NymanJ.S., and Mahadevan-JansenA.Prostate cancer metastases alter bone mineral and matrix composition independent of effects on bone architecture in mice—a quantitative study using microCT and Raman spectroscopy. Bone, 56, 454, 2013.
39.
VillasanteA., and Vunjak-NovakovicG.Bioengineered tumors. Bioengineered, 2015.
40.
ZhouZ., GuanH., DuanX., and KleinermanE.S.Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer, 104, 1713, 2005.
41.
ArnaldezF.I., and HelmanL.J.New strategies in ewing sarcoma: lost in translation? Clin Cancer Res, 20, 3050, 2014.
42.
BissellM.J., and HinesW.C.Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med, 17, 320, 2011.
43.
OdriG., KimP.P., LamoureuxF., CharrierC., BattagliaS., AmiaudJ., HeymannD., GouinF., and RediniF.Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration. BMC Cancer, 14, 169, 2014.
44.
OdriG.A., DumoucelS., PicardaG., BattagliaS., LamoureuxF., CorradiniN., RousseauJ., TirodeF., LaudK., DelattreO., GouinF., HeymannD., and RediniF.Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res, 70, 7610, 2010.
45.
ChapletM., DetryC., DeroanneC., FisherL.W., CastronovoV., and BellahceneA.Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition. Biochem J, 384, 591, 2004.
46.
HuL., WenY., XuJ., WuT., ZhangC., WangJ., DuJ., and WangS.Pretreatment with bisphosphonate enhances osteogenesis of bone marrow mesenchymal stem cells. Stem Cells Dev, 26, 123, 2017.
47.
SchuesslerT.K., ChanX.Y., ChenH.J., JiK., ParkK.M., Roshan-GhiasA., SethiP., ThakurA., TianX., VillasanteA., ZervantonakisI.K., MooreN.M., NagaharaL.A., and KuhnN.Z.Biomimetic tissue engineered systems for advancing cancer research: NCI Strategic Workshop Report. Cancer Res, 74, 5359, 2014.
48.
ZhangH., XueC., ShahR., BerminghamK., HinkleC.C., LiW., RodriguesA., Tabita-MartinezJ., MillarJ.S., CuchelM., PashosE.E., LiuY., YanR., YangW., GosaiS.J., VanDornD., ChouS.T., GregoryB.D., MorriseyE.E., LiM., RaderD.J., and ReillyM.P.Functional analysis and transcriptomic profiling of iPSC-derived macrophages and their application in modeling Mendelian disease. Circ Res, 117, 17, 2015.
49.
SousaS., and MaattaJ.The role of tumour-associated macrophages in bone metastasis. J Bone Oncol, 5, 135, 2016.
50.
GraysonW.L., BhumiratanaS., CannizzaroC., ChaoP.H., LennonD.P., CaplanA.I., and Vunjak-NovakovicG.Effects of initial seeding density and fluid perfusion rate on formation of tissue-engineered bone. Tissue Eng Part A, 14, 1809, 2008.
51.
VillasanteA., Marturano-KruikA., and Vunjak-NovakovicG.Bioengineered human tumor within a bone niche. Biomaterials, 35, 5785, 2014.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
